Find Clinical Trial

Home » Find Clinical Trials » A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

← Back

Study Phase	Phase 3

Therapeutic Area	Cancers

Indication	Acute Myeloid Leukemia

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	AG-120, Ivosidenib

Active Substance Code	AG-120

Protocol Code	AG120-C-009

EudraCT Code	2016-004907-30

NCT Code	NCT03173248

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.